• Mashup Score: 1
    myelocast - 7 month(s) ago

    A new Flutter project.

    Tweet Tweets with this article
    • RT @rexprem: If you want to estimate risk of progression in #myeloma, #SMM and #MGUS. Please visit https://t.co/gdgK0qwI2Q. Amazing work by…

  • Mashup Score: 0

    A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski

    Tweet Tweets with this article
    • The latest The Multiple Myeloma Daily! https://t.co/4MU1BXWeZD Thanks to @OncologyTimes @eaonc @AaronGoodman33 #bloodcancers #smm

  • Mashup Score: 0

    We are preparing a warm welcome in Madrid for the 2023 Intercepting Blood Cancers Meeting (IBC 2023). Taking place from 3-5 March 2023, the IBC 2023 Hybrid Meeting will provide a unique, interactive platform for presentations on key clinical trial data and expert clinical insights for early interventions in blood cancers and how this impacts outcomes for patients; three key topic tracks will…

    Tweet Tweets with this article
    • We’re helping launch the inaugural Intercepting Blood Cancers Workshop (#IBC2023) which is fast approaching🩸📣 Find out more & check out the agenda for the multiple #myeloma/#MGUS/#SMM sessions 👉 https://t.co/URJjMu3tHs Chairs: @IreneGhobrial & Jesús San-Miguel https://t.co/KHKGdT93uE

  • Mashup Score: 0

    iFrame is not supported! Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented i…

    Tweet Tweets with this article
    • Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study - What were the updated safety run-in results from the Ithaca study? @IreneGhobrial @DanaFarber @BrighamWomens #ASH22 #SMM #MultipleMyeloma Read and Share the Article Here: https://t.co/X262JRQ4cl https://t.co/sPGpFR4fHM

  • Mashup Score: 0

    Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented in the American Society of…

    Tweet Tweets with this article
    • Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study - What were the updated safety run-in results from the Ithaca study? @IreneGhobrial @DanaFarber @BrighamWomens #ASH22 #SMM #MultipleMyeloma Listen and Share the Audio Podcast Here: https://t.co/W3Uyk4h1RP https://t.co/zRTAa00aOD

  • Mashup Score: 0

    Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented in the American Society of…

    Tweet Tweets with this article
    • Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study - What were the updated safety run-in results from the Ithaca study? @IreneGhobrial @DanaFarber @BrighamWomens #ASH22 #SMM #MultipleMyeloma Watch and Share the Video Here: https://t.co/QLvEW3xVAj https://t.co/ZNXpCawOee

  • Mashup Score: 0

    Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to develop a new risk stratification system. We included…

    Tweet Tweets with this article
    • 💎SMM 20-2-20-FISH risk stratification 🔵M protein >2gm/dL 🔵BM clonal plasma cells >20% 🔵sFLC ratio >20 Score: Risk (2-year progression risk) 🔵0 → low risk (6%) 🔵1 → interm risk (18%) 🔵≥2→high risk (44%) @NaturePortfolio #mmsm #SMM #Medtwitter https://t.co/noduirKx45